-DOCSTART- -X- O
Chikungunya -X- _ B-Patient
fever -X- _ I-Patient
( -X- _ I-Patient
CHIKF -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
an -X- _ O
emerging -X- _ O
infectious -X- _ O
disease -X- _ O
caused -X- _ O
by -X- _ O
an -X- _ O
alphavirus -X- _ O
transmitted -X- _ O
by -X- _ O
Aedes -X- _ O
spp. -X- _ O
mosquitoes. -X- _ O
Because -X- _ O
mosquito -X- _ O
control -X- _ O
programs -X- _ O
are -X- _ O
not -X- _ O
highly -X- _ O
efficient -X- _ O
for -X- _ O
outbreak -X- _ O
containment -X- _ O
, -X- _ O
vaccines -X- _ O
are -X- _ O
essential -X- _ O
to -X- _ O
reduce -X- _ O
the -X- _ O
burden -X- _ O
of -X- _ O
disease. -X- _ O
Although -X- _ O
no -X- _ O
licensed -X- _ O
vaccine -X- _ O
against -X- _ O
CHIKF -X- _ O
is -X- _ O
yet -X- _ O
available -X- _ O
, -X- _ O
many -X- _ O
highly -X- _ O
promising -X- _ O
candidates -X- _ O
are -X- _ O
undergoing -X- _ O
preclinical -X- _ O
studies -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
few -X- _ O
of -X- _ O
them -X- _ O
have -X- _ O
been -X- _ O
tested -X- _ O
in -X- _ O
human -X- _ O
trials -X- _ O
of -X- _ O
phase -X- _ O
1 -X- _ O
or -X- _ O
2. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
recent -X- _ O
findings -X- _ O
regarding -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
a -X- _ O
CHIKF -X- _ O
vaccine -X- _ O
and -X- _ O
provide -X- _ O
an -X- _ O
update -X- _ O
on -X- _ O
vaccines -X- _ O
nearing -X- _ O
or -X- _ O
having -X- _ O
entered -X- _ O
clinical -X- _ O
trials. -X- _ O
We -X- _ O
also -X- _ O
address -X- _ O
needs -X- _ O
to -X- _ O
tackle -X- _ O
bottlenecks -X- _ O
to -X- _ O
vaccine -X- _ O
development—including -X- _ O
scientific -X- _ O
and -X- _ O
financial -X- _ O
barriers—and -X- _ O
to -X- _ O
accelerate -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
vaccines -X- _ O
; -X- _ O
several -X- _ O
actions -X- _ O
should -X- _ O
be -X- _ O
taken -X- _ O
: -X- _ O
( -X- _ O
i -X- _ O
) -X- _ O
design -X- _ B-Outcome
efficacy -X- _ I-Outcome
trials -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
conducted -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
course -X- _ I-Outcome
of -X- _ I-Outcome
outbreaks -X- _ I-Outcome
; -X- _ I-Outcome
( -X- _ I-Outcome
ii -X- _ I-Outcome
) -X- _ I-Outcome
evaluate -X- _ I-Outcome
the -X- _ I-Outcome
opportunity -X- _ I-Outcome
for -X- _ I-Outcome
adopting -X- _ I-Outcome
the -X- _ I-Outcome
“animal -X- _ I-Outcome
rule”for -X- _ I-Outcome
demonstration -X- _ I-Outcome
of -X- _ I-Outcome
efficacy -X- _ I-Outcome
for -X- _ I-Outcome
regulatory -X- _ I-Outcome
purposes -X- _ I-Outcome
; -X- _ O
( -X- _ O
iii -X- _ O
) -X- _ O
strengthen -X- _ B-Outcome
the -X- _ I-Outcome
collective -X- _ I-Outcome
commitment -X- _ I-Outcome
of -X- _ I-Outcome
nations -X- _ I-Outcome
, -X- _ I-Outcome
international -X- _ I-Outcome
organizations -X- _ I-Outcome
, -X- _ I-Outcome
potential -X- _ I-Outcome
donors -X- _ I-Outcome
and -X- _ I-Outcome
industry -X- _ I-Outcome
; -X- _ O
( -X- _ O
iv -X- _ O
) -X- _ O
stimulate -X- _ B-Outcome
public -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
private -X- _ I-Outcome
partnerships -X- _ I-Outcome
to -X- _ I-Outcome
invest -X- _ I-Outcome
in -X- _ I-Outcome
vaccine -X- _ I-Outcome
development -X- _ I-Outcome
and -X- _ I-Outcome
licensure -X- _ I-Outcome
; -X- _ O
and -X- _ O
( -X- _ O
v -X- _ O
) -X- _ O
identify -X- _ B-Outcome
potential -X- _ I-Outcome
markets -X- _ I-Outcome
for -X- _ I-Outcome
an -X- _ I-Outcome
effective -X- _ I-Outcome
and -X- _ I-Outcome
safe -X- _ I-Outcome
CHIKF -X- _ I-Outcome
vaccine -X- _ I-Outcome
. -X- _ O

